Literature DB >> 2499536

Endomysial antibodies in the diagnosis of celiac disease and the effect of gluten on antibody titers.

V Kumar1, A Lerner, J E Valeski, E H Beutner, T P Chorzelski, T Rossi.   

Abstract

Celiac disease, a common chronic gastrointestinal disorder, is gluten induced and is controlled with a gluten-free diet. While the management of CD with a gluten-free diet is quite effective, the diagnosis is rather difficult. The ESPGAN criteria for the diagnosis of CD seems to be tedious and time-consuming. Serological tests for IgA class endomysial antibodies, as detected by indirect immunofluorescence, on human and primate smooth muscles are specific and sensitive markers of celiac disease. Of all the specimens examined, endomysial antibodies were present in patients with gluten-sensitive enteropathy. These antibodies occurred in all active cases of celiac disease, in 90 percent suspected celiac patients where all the ESPGAN criteria has not been fulfilled. This contrasts to the presence of endomysial antibodies in 46 percent of confirmed and 17 percent of suspected celiac patients maintained on a gluten-free diet for various time intervals. Endomysial antibodies also occurred in all cases with chronic diarrhea and gut histology consistent with CD and 8% of asymptomatic family members of CD patients. None of the patients with other gastrointestinal and liver diseases had endomysial antibodies. These studies thus emphasize the specificity and sensitivity of endomysial antibodies for celiac disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499536     DOI: 10.3109/08820138909112261

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  10 in total

Review 1.  Endomysial antibody in the diagnosis and management of coeliac disease.

Authors:  M W James; B B Scott
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

2.  Anti-endomysial antibody negative celiac disease: does additional serological testing help?

Authors:  A Dahele; K Kingstone; J Bode; D Anderson; S Ghosh
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

3.  Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy.

Authors:  Julian A Abrams; Beverly Diamond; Heidrun Rotterdam; Peter H R Green
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

4.  Immunological diagnosis of childhood coeliac disease: comparison between antigliadin, antireticulin and antiendomysial antibodies.

Authors:  A Lerner; V Kumar; T C Iancu
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

5.  T cell receptor repertoire in the peripheral blood and intestinal mucosa of coeliac patients.

Authors:  N Lahat; A Ben-Nun; L Cohen; A Kinarty; A Lerner
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

6.  Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms.

Authors:  Kent D Katz; Shahrooz Rashtak; Brian D Lahr; L Joseph Melton; Patricia K Krause; Kristine Maggi; Nicholas J Talley; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2011-03-01       Impact factor: 10.864

Review 7.  Celiac disease-associated autoimmune endocrinopathies.

Authors:  V Kumar; M Rajadhyaksha; J Wortsman
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

8.  Celiac disease and epilepsy in pediatric patients.

Authors:  A Fois; M Vascotto; R M Di Bartolo; V Di Marco
Journal:  Childs Nerv Syst       Date:  1994-09       Impact factor: 1.475

9.  Endomysial antibody: is it the best screening test for coeliac disease?

Authors:  M Ferreira; S L Davies; M Butler; D Scott; M Clark; P Kumar
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

10.  Predictive value for coeliac disease of antibodies to gliadin, endomysium, and jejunum in patients attending for jejunal biopsy.

Authors:  S A McMillan; D J Haughton; J D Biggart; J D Edgar; K G Porter; T A McNeill
Journal:  BMJ       Date:  1991-11-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.